Market Intelligence, Clinical Progress, and High-Purity Reagents for NK Cell Checkpoint and Sézary Syndrome Therapeutic Development.
Target Biology & Key Features
- Resolved Target: KIR3DL2 (also known as CD158k)
- Functional Domains: Ig-like C2-type 1, Ig-like C2-type 2, Ig-like C2-type 3 (UniProt P43630)
- Key Mutations: rs3188286, rs633870, rs1048271 (dbSNP)
TarMart Solution Ecosystem & Related Targets
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KIR3DL2 ECD-Fc Fusion Protein Human, HEK293 Expressed (Native Glycosylation). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. |
View KIR3DL2 Products |
| Gene Delivery | KIR3DL2 Promise-ORF / Lentivirus Premade Particles Full-length human KIR3DL2 for stable cell line construction. |
View KIR3DL2 Products |
| Benchmark Ab | Anti-KIR3DL2 (Lacutamab / IPH4102 Sequence) Recombinant human IgG1 positive control. Sequence Verified. |
View KIR3DL2 Products |
| Validator | KIR3DL2 siRNA Set (3 unique sequences) For knockdown and specificity verification. |
View KIR3DL2 Products |
| Counter-Screen | KIR3DL1 ECD-Fc Protein Highly homologous subfamily member for selectivity and off-target profiling. |
View KIR3DL1 Products |
| Ligand | HLA-A3 ECD-Fc Protein Native ligand for KIR3DL2 blocking and binding assays. |
View HLA-A3 Products |
| Related Target A | NKG2A (CD159a) Complementary NK checkpoint for combination therapy screening. |
View NKG2A Products |
| Related Target B | CD47 Synergistic target for enhanced macrophage-mediated phagocytosis. |
View CD47 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Selectivity (KIR3DL2 vs. KIR3DL1) | Human KIR3DL2 and KIR3DL1 ECD proteins with >95% purity and matched domain architecture for precise cross-reactivity SPR/ELISA panels. |
| Ligand Competition & Blockade | High-purity HLA-A3 ECD-Fc available for custom blocking assay development against KIR3DL2 stable cell lines. |
| Cynomolgus Cross-Species Evaluation | Human and Cynomolgus KIR3DL2 ECD ortholog proteins with sequence identity confirmed for preclinical toxicology bridging studies. |
| Lack of Controls | Clinical Benchmark Antibody (Lacutamab/IPH4102 biosimilar) included for assay standardization and epitope binning. |
| False Positives / Specificity Gaps | Validated KIR3DL2 siRNA included for knockdown confirmation in target engagement studies. |
| NK Cell Line Engineering | Lentivirus particles with puromycin selection marker; Titer >10^8 TU/mL for stable KIR3DL2 expression in NK-92 or primary cells. |
| ADC Internalization Validation | ECD-Fc construct includes authentic transmembrane-proximal epitope regions for antibody binding and internalization kinetics. |
| Glycosylation-Dependent Epitope Recognition | HEK293 Expression (Native Glycosylation) ensures proper post-translational modifications for physiologically relevant assays. |
Live KIR3DL2 R&D Tracker
Global Clinical Landscape & Future Outlook
The race for KIR3DL2 therapeutics is intensifying, with Innate Pharma and Takeda leading clinical evaluation of first-in-class checkpoint blockade in Sézary syndrome and cutaneous T-cell lymphoma (CTCL). The pioneer anti-KIR3DL2 monoclonal antibody (Lacutamab/IPH4102) is advancing through late-phase trials, while the next wave of R&D is shifting toward NK-cell engagers, ADCC-enhanced Fc engineering, bispecifics (e.g., KIR3DL2 x CD30), antibody-drug conjugates (ADCs), and CAR-T therapies. Combination regimens with IL-15 superagonists, NKG2A/CD94 blockade, or CD47 inhibitors are being explored to overcome inhibitory tumor microenvironments. The unique overexpression of KIR3DL2 on malignant T-cells distinguishes it from normal NK cell biology, making it an attractive target for Sézary syndrome, CTCL, and potentially peripheral T-cell lymphomas (PTCL).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Checkpoint Blockade) | Innate Pharma / Takeda (Lacutamab) | Sézary Syndrome, CTCL | Blocking assay vs. HLA-A3/A11 using high-purity KIR3DL2 ECD-Fc and stable cell lines |
| Bispecific / NK Cell Engager | Innate Pharma, Affimed, Academic | Solid Tumors, CTCL, Lymphoma | Selectivity panel (KIR3DL2 vs. KIR3DL1) and cytotoxicity readouts using lentivirus-based stable target cells |
| ADCC-Fc Enhanced mAb | Innate Pharma (next-gen) | Relapsed / Refractory CTCL | FcγR binding validation requires benchmark antibody controls and NK effector cell lines |
| CAR-T / CAR-NK Therapy | Academic / Biotech pipelines | Refractory T-Cell Lymphomas, Solid & Liquid Tumors | Full-length KIR3DL2 lentivirus for expression validation and ligand-blocking specificity |
| ADC | Emerging Biotech | Hematological Malignancies, Lymphoma | Internalization assay using correctly folded ECD-Fc with native epitopes |
| Bispecific (KIR3DL2 x CD30) | Innate Pharma | Lymphoma | Heterodimer validation needing cross-reactive Abs and dual-target assays |